Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
3,5 MILJARD nieuwe aandelen zullen gedumpt worden door ESCOF (ca)
Volgen
ESPERITE : Esperite N.V. secures external financing of up to EUR 35 million of convertible notes with warrants drawable under certain conditions ACTUS NEWS•29/07/2020 à 09:45 Transaction highlights · Esperite NV secures an external financing of up to EUR 35 million through further private placements of convertible notes with share subscription warrants attached over a period of 36 months, subject to fulfillment of certain conditions · The Warrants, if exercised, are leading to an additional EUR 35 million proceeds over a period of 5 years · Bridge note of EUR 150,000 issued today · Subscription by European Small Caps Opportunities Fund, based in Australia · Before the end of September Esperite will convene a Shareholder Extraordinary General Meeting. · Esperite will propose a settlement to its creditors · Proceeds to be used to support Esperite' s restructuring plan to be approved by creditors The Netherlands, 28 July 2020 - Esperite N.V. (Euronext: ESP, "Esperite" or "the Issuer") announces today (i) the issuance of a bridge note of EUR 150,000 nominal value (the "Bridge Note") and (ii) the signing of a financing agreement allowing Esperite to draw up to EUR 35 million (the "Financing") private placement of convertible notes with share subscription warrants attached under certain conditions (the "Notes and Warrants") and having the characteristics detailed in Appendix 1 (the "Issuance Agreement"). The Bridge Note (issued) and the Notes and Warrants shall be subscribed by European Small Cap Opportunities Fund, a fund based in Australia (the "Investor"). The Bridge Note financing shall allow Esperite to initiate next steps of restructuring. With regards to the Financing, the first tranche of Notes and Warrants of a nominal amount of EUR 400,000 shall be issued after the approval of resolutions by the general meeting of shareholders of the Issuer and approval by Esperite' s creditors of a settlement amount to be paid overtime by the Issuer for their debt (the "Restructuring Plan Approval"). The second tranche of Notes and Warrants of a nominal amount of EUR 500,000 shall be issued after the approval of a prospectus by the AFM with regards to the new shares to be issued upon conversion of the Notes and exercise of the Warrants. Pursuant to the Issuance Agreement, the Investor has committed to subscribe up to EUR 35 million of Notes and Warrants over the next 36 months, subject to the fulfillment of certain conditions (the "Commitment"). The issuance of and subscription to Notes and Warrants shall be structured through the issuance by Esperite to the Investor of tranche warrants (the "Tranche Warrants") within 5 trading days from the Restructuring Plan Approval, whose characteristics are described in Appendix 1 to this press release. The terms and conditions of the Tranche Warrants, the Notes and the Warrants will be published on Esperite's website (www.esperite.com).
Appendix 1 Terms and conditions of the financing through the issuance of warrants giving access to convertible notes with share subscription warrants attached Legal framework of the transaction On July 27, 2020, the Issuer and the Investor entered into an issuance agreement pursuant to which the Investor has agreed to commit to fund the Issuer up to EUR 35,000,000 over the course of a period of 36 months from the Issuance Date (as defined below) by subscribing for up to 3,500 notes with a principal amount of EUR 10,000 each, which are convertible into ordinary shares of the Issuer, with share subscription warrants attached. The Commitment is subject to: - the adoption by the Issuer’s shareholders of the resolutions to be proposed for adoption at the next general meeting of shareholders of the Issuer to be held no later than September 30, 2020 in respect notably of (i) the approval to grant rights to subscribe for shares and to limit or exclude pre-emptive rights in respect of such grant of rights to the extent required in connection with the Issuance Agreement and (ii) the reduction of the Issuer’s share capital through the reduction of the nominal value of the Share to EUR 0.01; - the Restructuring Plan Approval. Main characteristics of the Tranche Warrants The issuance of 3,500 Tranche Warrants shall occur within 5 trading days from the Restructuring Plan Approval (the “Issuance Date”). Over the 36 months following the Issuance Date, provided that all the conditions to the delivery of a Request and the funding of a tranche (the "Conditions", see Note 1 below) have been satisfied (or waived by the Investor), the Issuer shall request for the disbursement of a tranche (the “Request”) by submitting a Request as follows: - for the first tranche, within five (5) trading days from the Restructuring Plan Approval; - for the second tranche, within five (5) trading days from the date of the approval of the listing Prospectus by the AFM. For the following tranches, the Issuer shall have the right (and not the obligation) to request for the disbursement of a tranche by submitting a Request on the earlier of: (i) the fifth (5th) trading day following the conversion (whether through one or several conversions) or redemption of all the Notes that had been issued in connection with previous tranches; or (ii) the 2-month anniversary date of the issuance of the previous tranche. Esperite may therefore request the exercise of Tranche Warrants in order to issue the Notes with Warrants in a first tranche of EUR 400,000 nominal amount and several subsequent tranches of EUR 500,000 nominal amount (amount which may be increased or decreased upon mutual consent). The exercise of one Tranche Warrant gives access to the subscription of one Note (having a nominal value of EUR 10,000) with Warrants attached at a subscription price of EUR 9,500.
Main characteristics of the Warrants The number of Warrants to be issued under each tranche will be such that, multiplied by their strike price (determined as described below), the resulting amount shall be equal to the principal amount of the tranche. The Warrants shall be immediately detached from the Notes. The Warrants shall have a maturity of 5 years from their respective issuance date (the “Exercise Period”). Each Warrant will give right to its holder, during the Exercise Period, to subscribe one new share of Esperite, subject to customary adjustments. Subject to customary ratchet provisions, the strike price of the Warrants will be equal to: • for the first, the second and the third tranches (the “Warrants 1”), 110% of the lower of (i) the lowest daily volume weighted average price of the share over the Pricing period preceding each request of such tranches and (ii) EUR 0.0272; and • for the subsequent tranches (the “Warrants 2”), 110% of the lowest daily volume weighted average price of the share over the Pricing Period preceding the Request (or the Tranche Warrant exercise date, in case of Tranche Warrants exercised at the discretion of the Investor). 1 shall mean the fifteen (15) consecutive trading days immediately preceding the relevant date to be considered in order to determine the conversion price or the Warrant 1 exercise price or the Warrant 2 exercise price. In the case of a conversion of Notes or upon the exercise of Tranche Warrants at the discretion of the Investor, Pricing Period shall mean the trading days during which the Investor (or the relevant Note or Tranche Warrant holder as the case may be) has not sold any Share in the market among the fifteen (15) consecutive trading days immediately preceding the applicable date.
The Warrants will not be admitted to trading on any financial market. New shares resulting from conversion of Notes or exercise of Warrants The new shares issued upon conversion of Notes or exercise of Warrants will be admitted to trading on Euronext as from their issuance, will carry immediate and current dividend rights and will be fully assimilated to and fungible with the existing shares (ISIN code NL0009272137). Esperite will publish and update on its website a follow-up table of the outstanding Tranche Warrants, Notes, Warrants and number of shares. Note 1: Conditions to the delivery of a Request and the funding of a tranche The right of Esperite to deliver a Request to the Investor and the obligation of the Investor to fund the requested tranche through the exercise of Tranche Warrants are subject to the fulfilment, on the date of such Request and on the date of funding of the requested tranche, of each of the following conditions (unless waived by the Investor): (i) no more than thirty-six (36) months shall have expired from the Issuance Date; (ii) the Notes of the previous tranches have been fully converted and/or redeemed for more than four (4) trading days or more than 2 months have elapsed since the previous Tranche Warrant exercise date. It is specified that this Condition shall not apply to the issuance of the second Tranche which shall be issued within five (5) trading days from the date of the approval of the listing Prospectus by the AFM; (iii) no material adverse change shall have occurred; (iv) no event that constitutes an early redemption event and no triggering event that would constitute an early redemption event if not cured during the applicable cure period, if any, shall be in existence; (v) the Issuer shall have at least: - two (2) times coverage of Shares (based on the conversion price) authorized, available and approved for issuance to the Investor and admission to trading on Euronext, increased, as the case may be, by the amount of any other outstanding Notes; and - one (1) time coverage of Shares authorized, available and approved for issuance to the Investor upon exercise of the maximum number of Warrants to be issued for the applicable Tranche; (vi) taking into account the Notes to be issued to the Investor under the requested tranche, the Investor shall not hold more than EUR 700,000 of aggregate principal amount of Notes;
no suspension of the trading of the Shares on Euronext (other than intra-day suspension at the request of Euronext Amsterdam under Euronext rules) shall have occurred for more than five (5) consecutive trading days over the ninety (90) preceding calendar days; (viii) the closing price and the daily VWAP on each of the five (5) preceding trading days shall be at least equal to 250% of the nominal value of the Shares; (ix) the average daily value traded of the Shares over the ten (10) preceding trading days shall be at least equal to EUR 20,000; (x) except with respect to the first Tranche, the AFM shall have approved a prospectus for the admission to trading of any shares to be issued upon conversion of the Notes or exercise of the Warrants; (xi) the final Restructuring Plan Approval shall have occurred; (xii) the Issuer has provided the Investor with all necessary information to fulfil its disclosure requirements with the AFM.
Voor de duidelijkheid: de nominale waarde wordt verlaagd naar 1 cent zodat er weer nieuwe aandelen kunnen worden uitgegeven en gedumpt.
DeZwarteRidder schreef op 29 juli 2020 12:50 :
Voor de duidelijkheid: de nominale waarde wordt verlaagd naar 1 cent zodat er weer nieuwe aandelen kunnen worden uitgegeven en gedumpt.
Tenzij aandeelhouders, rechters en/of Euronext dat blokkeren, zoals ooit bij AND met Roosland Beheer als "redder" gebeurde. Met als resultaat o.a. een opgelegde reverse split van 1:500 om van €0,01 (lager kon toentertijd niet) €5,00 te maken en het niet toelaten van bijgedrukte aandelen van €0,01 tot de notering. O.a.: uitspraken.rechtspraak.nl/inziendocum...
The right of the Investor to exercise Tranche Warrants at its sole and exclusive discretion will only be available regarding the exercise of 650 Tranche Warrants (i.e. up to an aggregate principal amount of EUR 6.5 million). The Tranche Warrants will not be admitted to trading on any financial market. Main characteristics of the Notes The Notes have a nominal value of EUR 10,000 each and will be subscribed at 95% of such nominal value. The Notes bear no interest and have a maturity of 12 months from their respective issuance date. Each Note gives its holder a conversion right (a “Conversion“) to receive ordinary shares. Upon a Conversion, the corresponding number of shares issued by Esperite shall be equal to: N = Nv / Cp - “N“: number of new and/or existing shares to be remitted to the Note holder (rounded down); - “Nv“: nominal value of the Note (EUR 10,000); - “Cp“: 90% of the lowest daily volume weighted-average price of the share over the Pricing Period1. At maturity any Note for which no Conversion has occurred shall be redeemed at par in cash by Esperite. Upon the occurrence of any event of default, any Note for which no Conversion has occurred shall be redeemed at 110% of par in cash by Esperite. The Notes will not be admitted to trading on any financial market. Main characteristics of the Warrants The number of Warrants to be issued under each tranche will be such that, multiplied by their strike price (determined as described below), the resulting amount shall be equal to the principal amount of the tranche. The Warrants shall be immediately detached from the Notes. The Warrants shall have a maturity of 5 years from their respective issuance date (the “Exercise Period”). Each Warrant will give right to its holder, during the Exercise Period, to subscribe one new share of Esperite, subject to customary adjustments. Subject to customary ratchet provisions, the strike price of the Warrants will be equal to: • for the first, the second and the third tranches (the “Warrants 1”), 110% of the lower of (i) the lowest daily volume weighted average price of the share over the Pricing period preceding each request of such tranches and (ii) EUR 0.0272; and • for the subsequent tranches (the “Warrants 2”), 110% of the lowest daily volume weighted average price of the share over the Pricing Period preceding the Request (or the Tranche Warrant exercise date, in case of Tranche Warrants exercised at the discretion of the Investor). 1 shall mean the fifteen (15) consecutive trading days immediately preceding
Als alles doorgaat krijgt ESCOF dus 5% korting op de convertibles en nog eens ca 10% op de daaruitkomende aandelen. In totaal dus ca 15% winst zonder enig risico, want de aandelen worden direct gedumpt na 'conversie'. De warrants (weten we nog van de vorige keer) hebben geen reële waarde en doen mee als versiering.
De aandelen hebben ook geen reële waarde, wtf dat ook mag zijn.
Ok ridder. Je hebt je punt gemaakt, maar dan...wat gaat er met die 35 miljoen gebeuren ?? Lijkt me dat die Aussies nu toch wel zeggenschap gaan eisen. En wat gaat Esperite doen..voor zover ik het lees wordt het een investeringsmaatschappij in de zorg..lekker breed begrip
Amarillo schreef op 30 juli 2020 07:36 :
Ok ridder. Je hebt je punt gemaakt, maar dan...wat gaat er met die 35 miljoen gebeuren ?? Lijkt me dat die Aussies nu toch wel zeggenschap gaan eisen. En wat gaat Esperite doen..voor zover ik het lees wordt het een investeringsmaatschappij in de zorg..lekker breed begrip
Je bent natuurlijk te lui om de oude draadjes door te lezen, dus ik zal het even samenvatten: ESCOF wil en mag geen echte zeggenschap hebben, het zal ze dus worst wezen wat Amar met het geld gaat doen. De 35 miljoen zal natuurlijk nooit gehaald worden, want de koers gaat door voortdurende dumpings natuurlijk zakken onder de 1 cent. Hoogstens krijgen ze een paar miljoen (als alles doorgaat). ESGOF heeft in verleden dus ca 40 M aandelen gehad en als ze die gehouden hadden dan waren ze nu voor ca 80% eigenaar van Esperite geweest. De hele deal zoals gisteren gepresenteerd, is 100% bedoeld om de kleine aandeelhouders voor de gek te houden en dat lukt aardig gezien reacties zoals die van jou.
Je moet gaan solliciteren bij de AFM of de afgeleide in Duitsland...daar kunnen ze nog wat van je leren
Al met al weet jij dus ook niet wat Amar met het geld gaat doen...daar ben ik nieuwsgierig naar..want bedrijfsactiviteiten zijn er nu niet natuurlijk
Amarillo schreef op 30 juli 2020 08:46 :
Al met al weet jij dus ook niet wat Amar met het geld gaat doen...daar ben ik nieuwsgierig naar..want bedrijfsactiviteiten zijn er nu niet natuurlijk
Als jij de vorige ronde van ESGOF had meegemaakt, dan zou je je daar niet druk over maken. Jij snapt niet hoe moeilijk en tijdrovend het is om geld op te halen bij een koers van een paar centen. Om b.v. 1 miljoen op te halen moeten er 100 miljoen aandelen gedumpt worden op een koers van 1 cent. Dus 100 dagen lang moeten er iedere dag 1 miljoen gedumpt worden.!! De vorige keer is ESGOF begonnen op ca 75 cent en die ronde heeft veel te weinig opgeleverd om Esperite te kunnen redden. Al dat geld is verdwenen in een zwart gat.
Wederom geen antwoord..beetje gezwam om de hete brei heen
Amarillo schreef op 30 juli 2020 09:10 :
Wederom geen antwoord..beetje gezwam om de hete brei heen
Amar heeft duidelijk figuren zoals jij nodig.
DeZwarteRidder schreef op 30 juli 2020 08:56 :
Jij snapt niet hoe moeilijk en tijdrovend het is om geld op te halen bij een koers van een paar centen.
Om b.v. 1 miljoen op te halen moeten er 100 miljoen aandelen gedumpt worden op een koers van 1 cent.
Je vergeet een aantal aspecten. Waaronder dat je, zonder dumpen, op papier van de extreme overwaardering kunt (proberen te) profiteren. Precies diezelfde overwaardering kan toestaan dat je een omgekeerde Kok-$huffle gaat dansen. Waarbij je hoopt dat de stroop van -50% door een dump, mét winst t.o.v. een cent, genoeg vliegen aantrekt. Omzetten ineens van 100+ mln. kunnen; zie o.a. Crescent. Of je zadelt een zakenrelatie met het probleem op. Ergens een negatief EV? Vul dat dan aan met de marktwaarde van een "inbreng". Iemands vorige voetbalclub wacht nog op de betaling van de transfersom van 50.000 euro? Bied een gulle betaling van 75.000 euro in beursgenoteerde aandelen aan. Zonder het effectieve rattengif van een reverse split is het wat het is en stelt het voor wat het is, maar door een bijna laagste prijs en extreme overwaardering wat het werkelijke risico - helaas - mee, en kun je je in bepaalde kringen trots presenteren als een ware, succesvolle multimiljonair. Tenslotte hoeft je bij een van 0,03 euro lang niet alles te dumpen om je kosten eruit te halen, als die kosten niet al onder de 0,01 lagen.
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Indices
AEX
874,02
-0,09%
EUR/USD
1,0697
-0,04%
FTSE 100
8.040,38
-0,06%
Germany40^
18.086,70
-0,01%
Gold spot
2.317,23
-0,21%
NY-Nasdaq Composite
15.712,75
+0,10%
Stijgers
Dalers